Image 1 of 1

080213_biofocus_660.jpg

Add to Cart Add to Lightbox Download
BioFocus pharmaceutical and bio-chemical laboratory, in Saffron Walden, UK. BioFocus is Galapagos N.V.s' service division and is based in the United Kingdom. BioFocus offers a full suite of target-to-drug discovery products and services to pharma, biotech and patient foundations - encompassing target and drug discovery through to the delivery of pre-clinical candidates. Galapagos, with it's headquarters in Mechelen, Belgium, has developed a target discovery platform that provides novel starting points for drug and antibody therapies, thereby addressing the industry's need for innovative, disease-modifying medicines. The Company's product portfolio consists mainly of new mode-of-action drugs in bone and joint diseases as well as programs in bone metastasis and cachexia. To enable the progression of a broad portfolio of programs, Galapagos has established risk sharing alliances with big pharma companies such as Johnson and Johnson, GlaxoSmithkline and Roche, and Janssen Pharmaceutica, in specific disease areas. Through an alliance with MorphoSys, Galapagos is also developing new antibody therapies in bone and joint diseases. (Photo © Jock Fistick)
Copyright
PHOTO © JOCK FISTICK
Image Size
5760x3940 / 2.2MB
Contained in galleries
Galapagos / Biofocus
BioFocus pharmaceutical and bio-chemical laboratory, in Saffron Walden, UK. BioFocus is Galapagos N.V.s' service division and is based in the United Kingdom. BioFocus offers a full suite of target-to-drug discovery products and services to pharma, biotech and patient foundations - encompassing target and drug discovery through to the delivery of pre-clinical candidates. Galapagos, with it's headquarters in Mechelen, Belgium, has developed a target discovery platform that provides novel starting points for drug and antibody therapies, thereby addressing the industry's need for innovative, disease-modifying medicines. The Company's product portfolio consists mainly of new mode-of-action drugs in bone and joint diseases as well as programs in bone metastasis and cachexia. To enable the progression of a broad portfolio of programs, Galapagos has established risk sharing alliances with big pharma companies such as Johnson and Johnson, GlaxoSmithkline and Roche, and Janssen Pharmaceutica, in specific disease areas. Through an alliance with MorphoSys, Galapagos is also developing new antibody therapies in bone and joint diseases. (Photo © Jock Fistick)